Clinical Trial VICCBMT1148


A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation (Consortium)

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCBMT1148
  • Open Date: 05/11/2012
  • Staging: Phase II
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To determine the clinical response rate of cutaneous sclerosis (skin and/or fascial thickening) after 6 months of initial therapy with either Imatinib or Rituximab.
  • Disease Sites: Hematologic
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Gleevec (Imatinib); Imatinib (Gleevec); Rituxan; Rituximab (Rituxan)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01309997
  • Secondary Protocol No: RDCRN6502



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.